Circ & Selenis Scale Circular Polyester in Europe
Textile-to-textile recycling pioneer Circ® has entered a strategic partnership with Selenis, a Portugal-based polyester manufacturer, to scale the industrial production of Circ® Polyester from end-of-life textiles in Europe.
Under this agreement, Selenis will toll and polymerize thousands of metric tons of Circ's recycled polyester, providing critical infrastructure to commercialize the fiber at large volumes across key apparel segments including activewear, basics, and fashion.
This collaboration not only accelerates Circ's dual-product platform—spanning recycled polyester and lyocell—but also enhances access to high-quality circular fibers for global mills and brands.
Peter Majeranowski, CEO of Circ®, stated, 'This partnership validates our strategy to scale two critical fiber alternatives simultaneously. With Selenis, we are well-positioned to deliver on the global demand for circular materials.'
Selenis, known for its expertise in high-performance polyester manufacturing, brings years of technical know-how and operational strength to the venture. The company has already made strides in bottle-to-bottle circularity and now strengthens its role in textile-to-textile recycling, with operations expanding in both the U.S. and Italy.
'This is about turning circularity from theory into industrial reality,' said Duarte Matos Gil, CEO of Selenis. 'We need systems where garments return as garments, not waste. And that requires both innovation and supportive legislation.'
Eduardo Santos, Global Head of Strategy at Selenis, added, 'Our decision to invest in textile circularity—even as our roots were in plastics—reflects our long-term vision. This alliance with Circ® is our next leap forward in making fashion truly sustainable.'
Together, Circ® and Selenis are building the infrastructure needed to close the loop on polyester production in the fashion industry—at scale, and across continents.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Wire
33 minutes ago
- The Wire
Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO, June 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties. "The acquisition of SomaLogic will enhance Illumina's presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024. This will strengthen the value of the NovaSeq X product today and unlock greater capabilities in the future," said Jacob Thaysen, chief executive officer of Illumina. "Illumina and SomaLogic have partnered closely for more than three years, and this combination increases our ability to serve our customers and accelerate our technology roadmap towards advanced biomarker discovery and disease profiling." This transaction builds on a co-development agreement Illumina established with SomaLogic in December 2021 to bring the SomaScan® Proteomics Assay onto Illumina's high-throughput next-generation-sequencing (NGS) platforms. Illumina Protein Prep is currently in use with nearly 40 early-access customers globally and will become available to all customers starting in the third quarter of 2025. Combining SomaLogic's proteomics technology with Illumina's scalable NGS ecosystem, DRAGEN™ software, and Illumina Connected Multiomics will accelerate the technology development roadmap for proteomics and reduce time and cost of proteomic research. "We are taking the scalability of NGS into proteomics," continued Thaysen. "Illumina will remain an open, accessible, and enabling NGS platform. The Company is committed to maintaining and supporting its existing proteomics partnerships as well as continuing to develop the sequencing ecosystem and supporting a wide variety of multiomics solutions." Scientific evidence* presented over the past year demonstrates the strength of SomaLogic's proteomics offerings in the areas of plexity, scalability, and technical reproducibility. In addition, researchers can generate significant and pivotal insights with high sensitivity, high throughput, and thousands of protein markers in a single experiment. SomaLogic has approximately 250 employees worldwide working in commercial, R&D, lab operations, manufacturing, and other roles. The company's Boulder, Colorado, facilities—including a CLIA- and CAP-certified lab, office, and manufacturing space—will be part of the purchase. SomaLogic has a global footprint serving customers. This transaction brings SomaLogic's aptamer-based affinity proteomics platform into Illumina's portfolio, enhancing Illumina's presence in a high-growth area within the proteomics market. The kitted NGS-based panels business will add a high-margin consumables revenue stream. Based on the projected closing date, Illumina expects this business to become profitable in 2027 on a non-GAAP operating income basis, and for non-GAAP operating margins to be in line with Illumina in 2028. Completion of the transaction is subject to customary closing conditions, including the receipt of required regulatory clearance. The parties intend to make the necessary filing under the Hart-Scott-Rodino Act in the United States in due course. Illumina expects to close the transaction in the first half of 2026. Until then, the companies will continue to operate as separate and independent entities. Goldman Sachs and Co. LLC is serving as financial advisor and Cravath, Swaine & Moore LLP is serving as legal advisor to Illumina. Centerview Partners LLC is serving as financial advisor to Standard BioTools, and Freshfields LLP and Richards, Layton & Finger P.C. are serving as its legal counsel. UBS Investment Bank is serving as financial advisor to the Special Committee of the Standard BioTools Board of Directors. Use of forward-looking statements This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) the completion of the proposed transaction on the anticipated terms and timeline, or at all, including the ability of the parties to obtain required regulatory clearance—such as under the Hart-Scott-Rodino Act in the United States or from government authorities that may have or assert jurisdiction outside the United States—and to satisfy other conditions to closing; (ii) the future conduct and growth of the business and the markets in which we operate, including the proteomics market; (iii) the success of products and services competitive with our own; (iv) our ability to successfully integrate SomaLogic into our existing operations and SomaLogic's technology and products into our portfolio; (v) our ability to sell SomaLogic's products and further develop SomaLogic's technology; (vi) our ability to successfully manage partner and customer relationships in the proteomics market; (vii) our ability to manufacture robust instrumentation and consumables including SomaLogic's products; (viii) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (ix) challenges inherent in developing, manufacturing, and launching new products and services; and (x) customer uptake of, and satisfaction with, new products and services, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter. About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube. *References: 1. Rooney MR, Chen J, Ballantyne CM, et al. Plasma proteomic comparisons change as coverage expands for SomaLogic and Olink. medRxiv. Preprint posted online July 12, 2024. doi:10.1101/2024.07.11.24310161 2. Kirsher DY, Chand S, Phong A, Nguyen B, Szoke BG, Ahadi S. The current landscape of plasma proteomics: technical advances, biological insights, and biomarker discovery. bioRxiv. Preprint posted online February 19, 2025. doi: 10.1101/2025.02.14.638375 Logo - (Disclaimer: The above press release comes to you under an arrangement with PRNewswire and PTI takes no editorial responsibility for the same.).
Hans India
an hour ago
- Hans India
Mobile exports show robust growth in FY26, reach $5.5 billion in April-May: Minister
New Delhi: Union Railways and Electronics and IT Minister Ashwini Vaishnaw on Wednesday said mobile exports from India witnessed a flying start to this fiscal, with the month of May clocking more than $3.09 billion in mobile exports from the country. In the April-May period this fiscal, the country saw $5.5 billion worth mobile exports. The government schemes like production-linked incentive (PLI) initiative have given a much-needed thrust to domestic manufacturing in recent years, with global tech giants like Apple and Samsung doubling down on ramping up their supply chains in the country. According to Vaishnaw, exports of mobile phones from India in May increased by over 74 per cent over the same month last year. 'FY26 off to a strong start: $3 billion smartphone exports in May alone (+74 per cent YoY); $5.5 billion exports in April-May; and $8.2 billion electronics exports in April-May (+47 per cent YoY),' the Union Minister posted on X social media platform. This stupendous growth has been achieved because India's competitive edge makes it a natural choice for tech giants like Apple and the US-based company has assured the government of its commitment to manufacture its products and boost the 'Make in India' initiative. Electronics exports from India has moved up from fifth position to third within one fiscal, owing to the transformative PLI scheme, according to Vaishnaw. Electronics exports clocked an all-time high of Rs 3.27 lakh crore in FY25, with mobile exports standing at Rs 2 lakh crore. 'Electronics exports moves up from fifth position to third within one fiscal. Three years in a row, electronics is India's fastest growing export amongst India's top 10,' Vaishnaw informed recently. He further stated that lakhs of new jobs have been created in the electronics ecosystem, especially for women, along with 'skilling, increasing DVA and Indian MSMEs joining global supply chains'. The electronics manufacturing industry has seen a five times growth in the last 10 years, surpassing Rs 11 lakh crore while the entire ecosystem has created 25 lakh jobs. In the last decade, electronics exports have risen six times to surpass Rs 3.25 lakh crore. The country has shown big companies like Apple the value of "Make in India'. The country has become a key hub for Apple's global supply chain in recent years.
Mint
an hour ago
- Mint
British Columbia's $183 Billion Fund Inks 45 Deals in Six Months
(Bloomberg) -- British Columbia Investment Management Corp. signed 45 deals during the past six months as the pension fund manager exploits the uncertainty in the market. 'All our asset classes are below the target allocations and have room to deploy,' Ramy Rayes, executive vice president of investment strategy and risk, said in an interview. 'While others might be stalling, we see good opportunities and good value too.' The money manager decided to 'start moving within the capital stack' across most of its asset classes, investing in infrastructure debt, convertible preferred shares within private equity and asset-backed lending. 'Right now being just in the equity sleeve or just purely in the debt sleeve may not get you the perfect risk-adjusted return,' Rayes said. Instead, BCI is investing in hybrid assets to maximize return and create downside protection, he said. Since the beginning of 2025, BCI has done 13 deals, while its real estate subsidiary QuadReal Property Group signed 32 pacts, Rayes said. Those investments include a take-private of Luxembourg-based BBGI Global Infrastructure SA and buying Maple Leaf Self Storage, a chain based in Western Canada. The fund's infrastructure holdings notched an 8.3% gain in the fiscal year ended March 31, while investments in private equity and private debt earned 13.4% and 10.2%, respectively. Overall, the pension fund manager returned 10% in the fiscal year, missing its benchmark of 12.3% and bringing net assets to C$251.6 billion ($183.3 billion), according to a statement Wednesday. BCI cut its US exposure to about 39% last year from 43.4% the previous year as it sold part of its equity portfolio, which is typically heavily tilted toward the country, Rayes said. The pension fund manager is also allocating capital to less volatile regions such as Europe and Asia amid President Donald Trump's erratic trade policies. Rayes said uncertainty about the world's largest economy means investors will either bid lower for assets or require higher growth to compensate. 'We might start underwriting a transaction in the beginning of the year; things change, the uncertainty increases and you get out,' he said. 'Pens down on the transaction.' While Trump's proposed so-called revenge tax has been delayed and revised by the US Senate, it adds another layer of unease. Known as Section 899, the provision has non-US investors worried that it could make investing in the country more expensive. BCI has done its own scenario analysis on the revenge tax. 'For our total portfolio at BCI, we could have an impact of 15 basis points as it stands today,' Rayes said, explaining that the final number may be zero in some cases but much higher in others. BCI, which invests the retirement savings of British Columbia's public sector workers, increased its exposure to Canada by seven percentage points to 37.8% during the year. That was driven by an increased allocation to the country's government bonds, private debt and real estate. Rayes said BCI would be interested in investing in Canadian infrastructure, such as airports. More stories like this are available on
